Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective June 1, 2026. These awards were approved by the Compensation Committee and granted under the Company's 2022 Inducement Plan as an inducement for employment. The stock options vest over four years and have an exercise price of $12.71 per share, equal to the last reported sale price on June 1, 2026.

Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer AG to evaluate OP-3136, Olema's investigational KAT6 inhibitor, in combination with Bayer's NUBEQA (darolutamide). The Phase 1b/2 study will assess the safety, tolerability, and preliminary anti-tumor activity in approximately 36 patients with metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in H2 2026. Under the agreement, Bayer will supply darolutamide, Olema will lead the study, and both companies will jointly own clinical data and inventions, while Olema retains full global commercial rights to OP-3136.

Olema Pharmaceuticals announced preliminary Phase 1 clinical data for OP-3136, a potent KAT6 inhibitor, demonstrating acceptable tolerability and promising anti-tumor activity as a monotherapy across multiple advanced solid tumor types. The study observed tumor shrinkage in over two-thirds of evaluable patients, including 3 partial responses (2 confirmed), with no dose-limiting toxicities or discontinuations due to adverse events. These results, supported by on-target engagement and predictable pharmacokinetics, reinforce confidence in OP-3136's potential and support ongoing Phase 1 evaluation, including combination studies. Olema will present these data and a Phase 3 trial-in-progress poster at the upcoming ASCO Annual Meeting.

Olema Pharmaceuticals, Inc. (Olema Oncology) announced its participation in three upcoming investor conferences in May and June 2026. The company will engage in fireside chats at the TD Cowen 7th Annual Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts and recordings of these presentations will be accessible on Olema's investor relations website.

Olema Pharmaceuticals reported a widened net loss of $53.1 million for the first quarter of 2026, compared to $30.4 million in the same period last year, primarily due to increased research and development expenses. The company's total operating expenses rose to $58.0 million. Despite the loss, Olema maintained a strong liquidity position with $505.3 million in cash, cash equivalents, and marketable securities, and raised $41.9 million through an at-the-market offering.

Olema Pharmaceuticals reported a net loss of $53.1 million for Q1 2026, an increase from $30.4 million in Q1 2025, driven by higher clinical development and research spending. The company ended the quarter with $505.3 million in cash, cash equivalents, and marketable securities. Key pipeline updates include anticipated top-line data from the Phase 3 OPERA-01 trial in fall 2026 and initial clinical data from the OP-3136 Phase 1 study to be presented at ASCO. Olema continues to enroll patients in the Phase 3 OPERA-02 trial and aims for its first commercial launch next year.

Olema Pharmaceuticals reported Q1 2026 financial results, including a net loss of $53.1 million, an increase from $30.4 million in Q1 2025, primarily due to higher R&D expenses. The company ended the quarter with $505.3 million in cash, cash equivalents, and marketable securities. Olema also provided significant pipeline updates, anticipating top-line data from its Phase 3 OPERA-01 trial for palazestrant this fall and presenting initial Phase 1 clinical data for OP-3136 at ASCO later this month. Patient enrollment continues for the Phase 3 OPERA-02 trial and other combination studies for palazestrant.

Olema Pharmaceuticals announced it granted stock options to five new employees to purchase an aggregate of 154,700 shares of common stock, effective May 1, 2026. These awards were approved by the Compensation Committee and granted under the Company's 2022 Inducement Plan as an inducement for new employment. The stock options vest over four years, with an exercise price of $14.32 per share.

Olema Pharmaceuticals, Inc. entered into a seven-year lease agreement for approximately 38,176 square feet of office and lab space to relocate its corporate headquarters by December 2026. The new premises, located on the fourth and fifth floors, will incur a total base rent of $18,506,651.76 over the initial term. The company also has an option to extend the lease for an additional five years and a right of first offer for expansion.

Olema Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Wednesday, June 17, 2026. Stockholders will vote on the election of four Class III directors, an advisory resolution on the compensation of named executive officers, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026. The record date for voting is April 23, 2026, with 87,346,132 shares outstanding.